MF59
MF59 is a biological therapy with 21 clinical trials. Currently 2 active trials ongoing. Historical success rate of 94.1%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
8
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
88.9%
16 of 18 finished
11.1%
2 ended early
2
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
Clinical Trials (21)
Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
H7N9 Mix and Match With MF59 in Healthy Adults
H5 Adult - Chiron Study of Bird Flu Vaccine
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 21